SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Technical analysis for shorts & longs -- Ignore unavailable to you. Want to Upgrade?


To: drsvelte who wrote (23589)9/9/1999 1:21:00 PM
From: drsvelte  Read Replies (1) | Respond to of 68324
 
IDEC Pharmaceuticals Corp. (IDPH) 124 7/16 -12 1/4: --UPDATE-- Salomon Smith Barney strongly reiterating their "buy" rating and sticking with their $78 mln Rituxan sales estimate; analyst feels management being too conservative, great buying opportunity; Merrill Lynch also defending the stock -- fundamentals excellent, reiterating "NT accumulate, LT buy" rating.....